Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment
MT newswire2026/10/07 12:2508:25 AM EDT, 10/07/2026 (MT Newswires) -- Natera (NTRA) said Wednesday that patient enrollment has begun for a trial using its Signatera test to identify patients who may need earlier intervention by detecting persistent molecular residual disease before radiographic progression. The company said the study will use Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, which is an aggressive type of skin cancer. It said the current standard of care is a combination immunotherapy until clinical progression. The company said the primary endpoint is progression-free survival. The study is sponsored by NYU Langone Health.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
